|
|
Blood, 15 December 2007, Vol. 110, No. 13, pp. 4436-4444.
Prepublished online as a Blood First Edition Paper on September 4, 2007; DOI 10.1182/blood-2007-05-088815.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
Monica L. Guzman1,
Xiaojie Li1,
Cheryl A. Corbett1,
Randall M. Rossi1,
Timothy Bushnell1,
Jane L. Liesveld1,
Josée Hébert2,
Fay Young1, and
Craig T. Jordan1
1 James P. Wilmot Cancer Center, University of Rochester, NY; and
2 Quebec Leukemia Cell Bank, Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montreal, QC
Leukemia is thought to arise from malignant stem cells, which have been described for acute and chronic myeloid leukemia (AML and CML) and for acute lymphoblastic leukemia (ALL). Leukemia stem cells (LSCs) are relatively resistant to current chemotherapy and likely contribute to disease relapse and progression. Consequently, the identification of drugs that can efficiently eradicate LSCs is an important priority. In the present study, we investigated the antileukemia activity of the compound TDZD-8. Analysis of primary AML, blast crisis CML (bcCML), ALL, and chronic lymphoblastic leukemia (CLL) specimens showed rapid induction of cell death upon treatment with TDZD-8. In addition, for myeloid leukemias, cytotoxicity was observed for phenotypically primitive cells, in vitro colony-forming progenitors, and LSCs as defined by xenotransplantation assays. In contrast, no significant toxicity was observed for normal hematopoietic stem and progenitor cells. Notably, cell death was frequently evident within 2 hours or less of TDZD-8 exposure. Cellular and molecular studies indicate that the mechanism by which TDZD-8 induces cell death involves rapid loss of membrane integrity, depletion of free thiols, and inhibition of both the PKC and FLT3 signaling pathways. We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
LSC defenses breached by chemical arsenal
- Tessa L. Holyoake and Mhairi Copland
Blood 2007 110: 4138-4139.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. E. Khuda, W. M. Loo, S. Janz, B. Van Ness, and L. D. Erickson
Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors
J. Immunol.,
December 1, 2008;
181(11):
7537 - 7549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Hassane, M. L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J. L. Liesveld, M. Carroll, and C. T. Jordan
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
Blood,
June 15, 2008;
111(12):
5654 - 5662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Blood,
March 1, 2008;
111(5):
2843 - 2853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
